Search
Diabetic Ketoacidosis
go.drugbank.com/conditions/DBCOND0000979Synonyms: Ketoacidosis in diabetes mellitusSonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Categories: Antineoplastic and Immunomodulating AgentsSynonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamideForeskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedDermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia.
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market. … [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … alfa can stimulate the production of neutrophils and thus reducing the severity and duration of neutropenia.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsVoretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigationalWhen used in genetic therapy, this virus is modified for the elimination of its negligible integrative capacity by the removal of *rep* and *cap* and the insertion of the desired gene with its promoter … [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095]
Synonyms: VN-rzylNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European … [L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with
Categories: nirmatrelvir and ritonavir, Amino Acids, Peptides, and ProteinsRevakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational[L52540] It has also been investigated in glaucoma,[A265115] retinitis pigmentosa (RP), and age-related macular degeneration.[A265125] … Revakinagene taroretcel is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF).
Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmidCategories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and ProteinsAbametapir
go.drugbank.com/drugs/DB11932ApprovedThe necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. … [A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target.
Categories: Scabicides, Insecticides and Repellents, Antiparasitic Products, Insecticides and RepellentsErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … [A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.
Categories: Ergot Alkaloids and Derivatives